See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Baseball
Natural Disasters
Stock Markets
UK Economy
South America
Tariffs
Donald Trump
Military
Social Media
Artificial Intelligence
Latin America
Taxes
Published • loading... • Updated

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer

Summary by ABC FOX Montana
SAN FRANCISCO and SUZHOU, China, March 23, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other…

15 Articles

All
Left
1
Center
2
Right
WFMZWFMZ
+11 Reposted by 11 other sources
Center

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer

SAN FRANCISCO and SUZHOU, China, March 23, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other…

·Pennsylvania, United States
Read Full Article
curetoday.comcuretoday.com

First Patient Dosed in Phase 3 Trial of IBI354 for Ovarian Cancer

The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.

Read Full Article
Clinical Trials ArenaClinical Trials Arena

Innovent Biologics doses first subject in trial of ovarian cancer therapy

Innovent Biologics has dosed the first subject in the Phase III HeriCare-Ovarian01 trial of IBI354 for treating PROC with HER2 expression.The post Innovent Biologics doses first subject in trial of ovarian cancer therapy appeared first on Clinical Trials Arena.

Read Full Article
vir.com.vnvir.com.vn

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 for Platinum-resistant Ovarian Cancer

SAN FRANCISCO and SUZHOU, China, March 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed with IBI354 (HER2 Monoclonal Antibody-Campto…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 67% of the sources are Center
67% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

ABC FOX Montana broke the news in Missoula, United States on Monday, March 24, 2025.
Sources are mostly out of (0)

Similar News Topics

Suzhou, China

Suzhou, China

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal